Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis

Cancer

Volumn 116, Issue 8, 2010, Pages 1947-1952

  Glantz, Michael J ^a   Van Horn, Alixis ^b   Fisher, Rebecca ^c   Chamberlain, Marc C ^d  

^a UNIVERSITY OF UTAH   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug delivery; Intralumbar chemotherapy; Intraventricular chemotherapy; Methotrexate; Neoplastic meningitis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; METHOTREXATE;

ADULT; ARTICLE; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DEMOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEPTOMENINX; MAJOR CLINICAL STUDY; MENINGITIS; MULTICENTER STUDY; NEOPLASTIC MENINGITIS; PERFORMANCE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; THERAPY EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; CYTARABINE; DELAYED-ACTION PREPARATIONS; DISEASE-FREE SURVIVAL; HUMANS; INJECTIONS, INTRAVENTRICULAR; MENINGEAL CARCINOMATOSIS; MENINGITIS; METHOTREXATE; NEOPLASMS; SPINAL PUNCTURE;

EID: 77950978123     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24921     Document Type: Article

References (34)

1. Chamberlain MC. Neoplastic meningitis. J Clin Oncol. 2005;23:3605-3613.
2. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5:1655-1662.
3. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11:561-569. (Pubitemid 23071056)
4. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (Depo-Cyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394-3402.
5. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110-3116. (Pubitemid 29470639)
6. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer. 2004;40:2726-2733. (Pubitemid 39574724)
7. Shapiro WR, Schmid M, Glantz M, Miller JJ. A randomized phase 3 of 4 study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis [abstract]. Proc ASCO. 2006;24(18 suppl pt I):65S. Abstract 1528.
8. Stapleton S, Blaney S. New agents for intrathecal administration. Cancer Invest. 2006;24:528-534.
9. Herrlinger U, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol. 1998; 38:233-239. (Pubitemid 28306213)
10. Coakham HB, Kernshead JT. Treatment of neoplastic meningitis by targeted radiation using 131I-radiolabeled monoclonal antibodies. J Neurooncol. 1998;38:225-232.
11. Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase 2 trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008;10:208-215.
12. Blaney SM, Balis FM, Berg S, et al. Intrathecal mafosphamide: a preclinical pharmacology and phase 1 trial. J Clin Oncol. 2005;23:1555-1563. (Pubitemid 46260045)
13. Gururangan S, Petros WP, Poussaint TY, et al. Phase 1 trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a pediatric brain tumor consortium study (PBTC-004). Clin Cancer Res. 2006;12:1540-1546.
14. Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 2006;106:2021-2027. (Pubitemid 43673219)
15. Rubensten JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25:1350-1356. (Pubitemid 46706881)
16. Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinetics. 2005;44:1-31. (Pubitemid 40096037)
17. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer. 1995;75: 2919-2931.
18. Chamberlain MC, Kormanik PA. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology. 1996;46:1674-1677. (Pubitemid 126425746)
19. Mason WP, Yeh SD, DeAngelis LM. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1998;50:438-444. (Pubitemid 28119786)
20. Bleyer WA, Drake JC, Chapner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med. 1973;289:770-773.
21. Bleyer WA. Clinical pharmacology of intrathecal methotrexate: I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep. 1977;61:703-708.
22. Bleyer WA. Clinical pharmacology of intrathecal methotrexate: II. An improved dosage regimen derived from agerelated pharmacokinetics. Cancer Treat Rep. 1977;61:1419-1425.
23. Kim S, Chatelut E, Kim JC, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993;11:2186-2193. (Pubitemid 23332256)
24. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161-166.
25. Lishner M, Perrin RG, Feld R, et al. Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Arch Intern Med. 1990;150:173-176.
26. Obbens EA, Leavens ME, Beal JW, Lee YY. Ommaya reservoirs in 387 cancer patients: a 15-year experience. Neurology. 1985;35:1274-1278.
27. Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1998;89:172-173. (Pubitemid 27454587)
28. Sandberg DI, Bilsky MH, Soweidane MM, et al. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery. 2000;47:49-54.
29. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC. Quality-of-life-adjusted survival comparison of sustained-release cytarabine (DepoCyt) versus intrathecal methotrexate for treatment of carcinomatous meningitis. Cancer. 2003;97:3053-3060.
30. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer: a clinical and pathological study. Arch Neurol. 1974;30:120-137.
31. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumor: experience with 90 patients. Cancer. 1982;49:759-772. (Pubitemid 12165435)
32. Rogers LR, Duchesneau PM, Nunez C, et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastases. Neurology. 1992;42:1239-1241.
33. Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar CSF cytology in adult patients with leptomeningeal metastases. Neuro Oncol. 2001;3:42-45.
34. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82:733-739.